BCPP || 100% Accurate Answers.
Alemtuzumab CI correct answers HIV infection and prolonged reductions of CD4 count
Alemtuzumab BW/REMS correct answers malignancies, infusion rxns, stroke, autoimmune
conditions
Cladribine CI correct answers HIV; active infections; pregnancy/breastfeeding
Timing of last dose of cladribine in P/L correct answers P: 6 months; L: 10 days
Fingolimod CI correct answers Qtc > 500 ms; class 1a or 3 antiarrhythmics; AV block/sick sinus
syndrome
Fingolomid/siponimod CI in last 6 months correct answers MI, unstable angina, stroke, TIA, HF
requiring hospitalization, class 3 or 4 HF
Interferon CI correct answers hypersensitivity to albumin, mannitol
Mitoxantrone BW correct answers bone marrow suppression and myocardial toxicities
Natalizumab CI/BW correct answers PML
Ocrelizumab CI correct answers active Hep B
Siponimod CI correct answers CYP2C9 3/3 genotype
Teriflunomide CI correct answers severe liver toxicity; pregnancy or lack of contraception (up to
2 years after last dose)
MS meds with liver toxicity correct answers fingolimad; interferon; natalizumab; ocrelizumab;
siponimod; teriflunomide
MS meds with PML risk correct answers dimethyl fumarate; fingolimad; natalizumab (major);
ocrelizumab
Brivaracetam MOA correct answers Binds to synaptic vesicle protein SV2A
CBZ/OXC/eslicarbazepine MOA correct answers fast sodium blocker
Ethosuximide MOA correct answers Blocks T-type Ca2+ channels
Everolimus MOA correct answers mTOR inhibitor
Felbamate MOA correct answers fast sodium blocker; T type calcium blocker; glutamate
receptor blocker; increases GABA
Alemtuzumab CI correct answers HIV infection and prolonged reductions of CD4 count
Alemtuzumab BW/REMS correct answers malignancies, infusion rxns, stroke, autoimmune
conditions
Cladribine CI correct answers HIV; active infections; pregnancy/breastfeeding
Timing of last dose of cladribine in P/L correct answers P: 6 months; L: 10 days
Fingolimod CI correct answers Qtc > 500 ms; class 1a or 3 antiarrhythmics; AV block/sick sinus
syndrome
Fingolomid/siponimod CI in last 6 months correct answers MI, unstable angina, stroke, TIA, HF
requiring hospitalization, class 3 or 4 HF
Interferon CI correct answers hypersensitivity to albumin, mannitol
Mitoxantrone BW correct answers bone marrow suppression and myocardial toxicities
Natalizumab CI/BW correct answers PML
Ocrelizumab CI correct answers active Hep B
Siponimod CI correct answers CYP2C9 3/3 genotype
Teriflunomide CI correct answers severe liver toxicity; pregnancy or lack of contraception (up to
2 years after last dose)
MS meds with liver toxicity correct answers fingolimad; interferon; natalizumab; ocrelizumab;
siponimod; teriflunomide
MS meds with PML risk correct answers dimethyl fumarate; fingolimad; natalizumab (major);
ocrelizumab
Brivaracetam MOA correct answers Binds to synaptic vesicle protein SV2A
CBZ/OXC/eslicarbazepine MOA correct answers fast sodium blocker
Ethosuximide MOA correct answers Blocks T-type Ca2+ channels
Everolimus MOA correct answers mTOR inhibitor
Felbamate MOA correct answers fast sodium blocker; T type calcium blocker; glutamate
receptor blocker; increases GABA
